InvestSMART

Oncosil Medical Limited (ASX: OSL) - Share Price

Current share price for OSL : $1.150 0.11 (8.73%)+

OncoSil Medical (OSL), an ASX-listed company, is a global medical device company focused on Interventional Oncology and focuses on improving the outcomes for people living with cancer by utilizing the selected and targeted intratumoural placement of Phosphorous-32 (32P) Microparticles in addition to chemotherapy.

OSL General Information +

ASX Code OSL
Website N/A
Industry/Sector Life Sciences Tools & Services
Market Cap ($M) 35
OSL Share Price $1.150
Day High $1.280
Day Low $1.150
Last Close $1.260
OSL Share Price Movement $0.11 ( 8.73% )
Prices as at 16:36, 22 Jul 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Oncosil Medical Limited (OSL) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Oncosil Medical Limited (OSL) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Oncosil Medical Limited (OSL) price-sensitive announcements

OSL - OncoSil Medical Completes Manufacturing Validation
OncoSil Medical Limited has successfully completed its manufacturing validation program, m
Oncosil Medical Limited (OSL)
13 Jul 2026 | 8:39 AM
OSL - OncoSil Medical Files for FDA Approval
OncoSil Medical Limited has announced its submission of the Humanitarian Device Exemption
Oncosil Medical Limited (OSL)
3 Jul 2026 | 8:27 AM
OSL - OncoSil Selected for Major European Pancreatic Cancer Study
OncoSil Medical Limited has been selected to participate in the PALACROS consortium, a maj
Oncosil Medical Limited (OSL)
2 Jul 2026 | 8:46 AM
OSL - OncoSil progresses HDE with US FDA
OncoSil Medical Limited announced that the U.S. FDA has confirmed all outstanding question
Oncosil Medical Limited (OSL)
9 Jun 2026 | 9:48 AM

Oncosil Medical Limited (OSL) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+
Price at
release+
Current
price+
Gain/Loss View
Oncosil Medical Limited (OSL)
ORDINARY FULLY PAID
Health Care $36 OncoSil Medical Receives Saudi Arabia FDA Approval 20 Jul 2026 8:31AM $1.450 $1.150 fallen by 20.69%
Oncosil Medical Limited (OSL)
ORDINARY FULLY PAID
Health Care $36 Application for quotation of securities - OSL 17 Jul 2026 3:31PM $1.460 $1.150 fallen by 21.23%
Oncosil Medical Limited (OSL)
ORDINARY FULLY PAID
Health Care $36 Investor Presentation 15 Jul 2026 8:57AM $1.375 $1.150 fallen by 16.36%
Oncosil Medical Limited (OSL)
ORDINARY FULLY PAID
Health Care $36 OSPREY Registry Abstract Accepted for EANM 2026 Congress 14 Jul 2026 8:54AM $1.400 $1.150 fallen by 17.86%
Oncosil Medical Limited (OSL)
ORDINARY FULLY PAID
Health Care $36 OncoSil Medical Completes Manufacturing Validation 13 Jul 2026 8:39AM $1.320 $1.150 fallen by 12.88%
Oncosil Medical Limited (OSL)
ORDINARY FULLY PAID
Health Care $36 TRIPP-FFX Results Presented at ESMO GI 2026 6 Jul 2026 8:49AM $0.985 $1.150 risen by 16.75%

OSL Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$15.10 -$137.40 -38.10% 0.00 0.00 0.00% 0.0%
2024A -$12.38 -$221.80 -41.20% 0.00 0.00 0.00% 0.0%
2023A -$11.34 -$377.20 -6.60% 0.00 0.00 0.00% 0.0%

OSL Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
Oncosil Medical Limited (OSL) $40M -0.3805 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%

OSL Directors

Name Position Start Date
Mr Nigel Lange Chief Executive Officer, Managing Director 21 Jan 2021
Mr Peter James MacDonald Hall Non-Executive Director 1 Oct 2024
Ms Lelde Smits Non-Executive Director 15 Jan 2025
Dr Thomas (Tom) Duthy Non-Executive Director, Non-Executive Chairman 11 Jul 2025

Oncosil Medical Limited (OSL) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
17 Mar 2026 SMITS, Lelde Issued Indirect Shares 44,120 $0.680 $30,001.600
17 Mar 2026 DUTHY, Thomas (Tom) Issued Indirect Shares 50,537 $0.680 $34,365.160
19 Jun 2025 SMITS, Lelde Issued Options 7,500 $12.000 $90,000.000

See all changes in directors' interest & trades for Oncosil Medical Limited (OSL) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

OSL Management

Name Position
Mr Douglas Cubbin Chairman
Nova Taylor Joint Company Secretary
Tim Luscombe Joint Company Secretary

OSL Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Oncosil Medical Limited (OSL). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
3,422,619 (18.18%) Washington H. Soul Pattinson and Company Limited
1,304,473 (6.93%) State Street Australia Ltd

OSL Calendar of Events

Date Event
23 February 2027 Report (Interim)
22 October 2026 Report (Annual)
28 August 2026 Report (Annual)
28 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.